DEPAKOTE ER: Well Tolerated in Migraine Prophylaxis

DEPAKOTE Adverse Events in Migraine Patients1,3 STUDY DESIGN: In 2 placebo-controlled migraine prevention clinical trials and their long-term extension, DEPAKOTE delayed-release tablets were generally well tolerated with most adverse events rated as mild to moderate in severity.

DEPAKOTE ER Adverse Events in Migraine Patients1 STUDY DESIGN: In a multicenter, randomized, double-blind, placebo-controlled clinical trial, DEPAKOTE ER was well tolerated in the preventive treatment of migraine headache.

Click Here for Indications and Important Safety Information Including Boxed Warnings

Click Here for Full Prescribing Information